@article{TCR21086,
author = {Jack P. Gleeson and Niamh M. Keegan and Patrick G. Morris},
title = {Neoadjuvant pertuzumab, T-DM1, weekly paclitaxel and possible anthracyclines in HER2 positive early breast cancer treatment— questions from the KRISTINE study},
journal = {Translational Cancer Research},
volume = {7},
number = {Suppl 5},
year = {2018},
keywords = {},
abstract = {For over a decade, the standard of care for early breast cancer that overexpresses human epidermal growth factor 2 (HER2) has been cytotoxic chemotherapy in combination with HER2 targeted agents.},
issn = {2219-6803}, url = {https://tcr.amegroups.org/article/view/21086}
}